Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: Multi-centre phase I/II study

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 995-1004

  Loriot, Yohann ^a   Fizazi, Karim ^a   Jones, Robert J ^b   Van Den Brande, Jan ^c   Molife, Rhoda L ^d   Omlin, Aurelius ^d   James, Nicholas D ^e   Baskin Bey, Edwina ^f   Heeringa, Marten ^f   Baron, Benoit ^f   Holtkamp, Gertjan M ^f   Ouatas, Taoufik ^f   De Bono, Johann S ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f Astellas Pharma Global Development   (Netherlands)

Author keywords

17beta hydroxysteroid dehydrogenase type 5; AKR1C3; Androgen deprivation therapy; Androgen synthesis; Castration resistant prostate cancer; Testosterone

Indexed keywords

1-(1-((5-METHOXY-1H-INDOL-2-YL)CARBONYL)PIPERIDIN-4-YL)-2-METHYLPROPAN-2-OL; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; ANDROSTANOLONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PIPERIDINE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CELL COUNT; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

3-HYDROXYSTEROID DEHYDROGENASES; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CELL COUNT; DIHYDROTESTOSTERONE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INDOLES; KALLIKREINS; MALE; MIDDLE AGED; PIPERIDINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84927652789     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0101-x     Document Type: Article

References (17)

1. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, Panel Members (2013) Prostate cancer: ESMO consensus conference guidelines 2012. Ann Oncol 24:1141-1162. doi:10.1093/annonc/mds624
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van der Kwast TH, Wiegel T, Zattoni F (2013) EAU guidelines on prostate cancer. Update March 2013. European Association of Urology. http://www.uroweb.org/guidelines/online-guidelines/. Accessed 14 November 2013
3. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85
4. Massard C, Fizazi K (2011) Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876-3883
5. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R (2013) Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res 19:5613-5625
6. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825
7. Hamid ARAH, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FCGJ, Sedelaar JPM, Schalken JA (2012) Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med 18:1449-1455
8. Pfeiffer MJ, Smit FP, Sedelaar JPM, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17:657-664
9. Yu CC, Huang SP, Lee YC, Huang CY, Liu CC, Hour TC, Huang CN, You BJ, Chang TY, Huang CH, Bao BY (2013) Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS One 8:e54627
10. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925
11. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71:6503-6513
12. Adeniji AO, Chen M, Penning TM (2013) AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 137:136-149
13. Kikuchi A, Enjo K, Furutani T, Azami H, Nimi T, Kuromitsu S, Kamiyma Y (2013) ASP9521, a novel, selective, orally bioavailable AKR1C3 (type 5,17β-hydroxysteroid dehydrogenase) inhibitor: In vitro and in vivo characterization. J Clin Oncol 31 (15S):319 s (abs.5046)
14. Watanabe K, Kakefuda A, YasudaM, Enjo K, Kikuchi A, Furutani T, Naritomi Y, Otsuka Y, Okada M, Ohta M (2013) Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl) carbonyl] piperidin-4-yl} propan-2-ol: A novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorg Med Chem 21:5261-5270
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
16. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108:13728-13733
17. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71:1486-1496